Ultragenyx Pharmaceutical (RARE) EBITDA Margin Growth (1y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,609.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1,536.00 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -957.00 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 8,807.00 |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | -2,139.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,139.00 |
| Dec 31, 2025 | 1,963.00 |
| Sep 30, 2025 | -1,223.00 |
| Jun 30, 2025 | 1,434.00 |
| Mar 31, 2025 | 4,905.00 |
| Dec 31, 2024 | 2,155.00 |
| Sep 30, 2024 | 5,336.00 |
| Jun 30, 2024 | 5,746.00 |
| Mar 31, 2024 | 142.00 |
| Dec 31, 2023 | 4,508.00 |
| Sep 30, 2023 | 10,016.00 |
| Jun 30, 2023 | 2,188.00 |
| Mar 31, 2023 | 1,758.00 |
| Dec 31, 2022 | -1,792.00 |
| Sep 30, 2022 | -13,812.00 |
| Jun 30, 2022 | -6,331.00 |
| Mar 31, 2022 | -6,371.00 |
| Dec 31, 2021 | -1,804.00 |
| Sep 30, 2021 | -4,826.00 |
| Jun 30, 2021 | 701.00 |
| Mar 31, 2021 | 22,511.00 |
| Dec 31, 2020 | 16,041.00 |
| Sep 30, 2020 | 39,573.00 |
| Jun 30, 2020 | 36,357.00 |
| Mar 31, 2020 | 21,364.00 |
| Dec 31, 2019 | 29,020.00 |
| Sep 30, 2019 | 30,461.00 |
| Jun 30, 2019 | 27,600.00 |
| Mar 31, 2019 | 35,772.00 |
| Dec 31, 2018 | 405,558.00 |
| Sep 30, 2018 | 4.15 Mn |
| Dec 31, 2017 | 140.64 Mn |
| Sep 30, 2017 | 1.70 Mn |